Audit: QRS - Sarcosine for Health & Longevity

Audit conducted on 11/03/2026 14:39 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	97
Passed	87
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Lede, Protocol, Time to effect, gates, tiers, markers and cadence all trace to ER Conclusion, Therapeutic Protocol, Practical Considerations, Key Interactions & Contraindications and Monitoring sections
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious ER phrasing kept: “No study compared timing”, “no time course exists for aging-related outcomes”, “possible mild hemoglobin drop”, “untested in humans”
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No claim strengthened or softened; lede keeps “though reviews disagree” and “open questions”; contraindications carried as stated in ER
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications from ER populations list, interactions from documented/theoretical groups, risks from Potential Risks section; no modifying factor relabeled
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, NCT IDs, expert or brand names; drug names (citalopram, venlafaxine, bitopertin, iclepertin, etc.) appear in the ER for the same facts

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-weighted tone matching the ER
2.2	The tone of the QRS is expert, accessible, objective, and data-driven	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses the reader directly — it presents evidence, not guidance	🟢	No second-person address anywhere
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms appear only inside verbatim ER labels (GlyT1, NMDA, SSRIs, SAMe, autophagy)
2.8	Information is presented in a concise and very compact manner	🟢
2.9	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.10	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.11	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Lede separates psychiatric evidence from the untested longevity rationale
2.13	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No “anti-aging” wording
2.14	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No colloquial route or adverse-event wording

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and column headers unchanged
3.2	Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name	🟢	All template data-qrs-var names present; marker_# and qualitative_item_# expanded to 1-4 per 14.2/15.2
3.3	Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well	🟢	Diff against template shows changes only inside data-qrs-var spans, display:none on empty tier spans, and metadata values

4. Formatting

#	Description	Result	Comments
4.1	An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over.	🟢	Empty tiers (Medium benefit, High/Medium risk) hidden; no empty-state phrasing
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels (“Standard dose”, “Single or split dose”, “Time of day”), interaction labels and qualitative labels use ER bold labels
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Only glosses and some example names trimmed from parenthetical label lists
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit.	🟢	No trailing dash clauses, glosses, untrimmed example lists or repetitions

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only quoted value is duration “00:02”, which contains a colon
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	26.10.25 matches QRS.md version
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	2026-1103-1417
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name	🟢	Opus
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model	🟢	Opus 5.5
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Sarcosine for Health & Longevity - Quick Reference Sheet”
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	11/03/2026
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Opus 5.5
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “Sarcosine, a glycine-derived supplement studied for mental illness and aging”
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Covers mechanism, mood/schizophrenia evidence, longevity rationale and safety open questions from the Conclusion
7.3	[at_a_glance] is no longer than 70 words	🟢	70 words
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; plain wording (“psychosis medicines”, “brain receptor”)
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All four ER populations to avoid listed
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“including active surveillance” qualifier kept; only the gloss on it dropped
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section is populated
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section not empty

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found	🟢	Clozapine, SSRIs/SNRIs and sodium benzoate listed; non-clozapine antipsychotics (“No interaction found”) correctly excluded
9.3	[caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label	🟢	All four theoretical interactions listed
9.4	The ER placeholder “None identified” is never an item: it means that group is empty	🟢
9.5	Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause	🟢
9.6	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.7	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists preserved in trimmed form
9.8	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation
9.9	If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty.	N/A	ER theoretical group is not empty
9.10	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section is populated
9.11	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g.	N/A	Section not empty

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Therapeutic Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from that section	🟢	Standard dose, split dosing, time of day
10.3	If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	N/A	ER gives at least three actionable aspects
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The three time-to-effect statements in ER Practical Considerations
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Schizophrenia and low mood (High) precede obsessive-compulsive symptoms (Low)
11.3	If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	N/A	ER gives three aspects
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty.	N/A	ER provides time-to-effect information

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	Medium tier hidden with display:none

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	“(GlyT1-Inhibitor Class Effect)” stripped from Lower hemoglobin
13.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	High and Medium tiers hidden with display:none

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢
14.2	All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names	🟢	All four ER biomarkers listed as rows 1-4
14.3	[marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER”	🟢	Targets match ER ranges
14.4	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty.	🟢
14.5	If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template	N/A	ER names measurable biomarkers

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢
15.2	All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 …	🟢	All four ER qualitative markers listed
15.3	If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template	N/A	ER names qualitative markers

Issues 11/03/2026 14:39

Pass rate 100.00%. No issues found.

Issues 11/03/2026 14:35

1. 4.5 — Untrimmed theoretical example lists: The theoretical interactions at lines 573–574 carry the ER’s full four-name example lists, “(ketamine, esketamine, memantine, dextromethorphan)” and “(betaine, dimethylglycine, choline, SAMe)”, untrimmed.

Fixes 11/03/2026 14:35

1. 4.5 — Trimmed theoretical example lists: Shortened “NMDA antagonists (ketamine, esketamine, memantine, dextromethorphan)” to “(ketamine, dextromethorphan)” and “(betaine, dimethylglycine, choline, SAMe)” to “(betaine, choline, SAMe)”.

Issues 11/03/2026 14:31

1. 1.2 — Hemoglobin hedge dropped in lede: At-a-glance (line 439) reduces the ER Conclusion’s “a possible mild drop in hemoglobin seen with related drugs” to “possible hemoglobin drop”, losing “mild” and the analogue-only basis of the signal.

Fixes 11/03/2026 14:31

1. 1.2 — Hemoglobin hedge restored in lede: Changed “possible hemoglobin drop” to “possible mild hemoglobin drop seen with related drugs” in at_a_glance, tightening other wording (“dietary supplement” → “supplement”, “brain receptor involved in learning and mood” → “learning- and mood-related brain receptor”, “support improvement in” → “support improved”, “open questions are” → “open questions:”) to stay within 70 words.

Issues 11/03/2026 14:27

1. 2.7 — Jargon in Monitoring Why: Marker 1 Why at QRS line 622 reads “Safety check: GlyT1-inhibitor class lowers hemoglobin”; “GlyT1-inhibitor class” is unnecessary specialist jargon outside any ER label carried verbatim.

Fixes 11/03/2026 14:27

1. 2.7 — Jargon in Monitoring Why: Replaced marker 1 Why “Safety check: GlyT1-inhibitor class lowers hemoglobin” with “Safety check: related drugs lower hemoglobin”, the ER Conclusion’s plain wording.

Issues 11/03/2026 14:23

1. 7.2 — Lede omits safety caveats: The at_a_glance at line 439 ends on “Short-term safety looks reassuring.” and drops the Conclusion’s open safety questions (mood over-activation with certain antidepressants, possible hemoglobin drop, laboratory prostate cancer cell spread), which an execution-oriented summary needs.

Fixes 11/03/2026 14:23

1. 7.2 — Lede safety caveats added: Rewrote at_a_glance (still 70 words) to end with the Conclusion’s open safety questions (rare mood over-activation with certain antidepressants, possible hemoglobin drop, laboratory prostate cancer spread), trimming “inexpensive”, “and cell” and the sharper-thinking clause to fit.

Issues 11/03/2026 14:19

1. 1.1 — Overgeneralized pooled-trial claim: action_1_sub (line 456) says 2 g/day was “Used in every pooled trial”, while the ER (line 305) limits this to the trials pooled by Marchi 2021.
2. 4.5 — Gloss repeats time value: time_2_sub (line 506) “Compared with a standard antidepressant” is an optional gloss repeating time_2_value “Faster remission than citalopram”.
3. 7.1 — Use not stated: The lede (line 439) says what sarcosine is and how it acts but not what it is used for before the evidence verdict.
4. 7.4 — Disagreement scope ambiguous: “though reviews disagree” (line 439) reads as covering low mood too; the ER Conclusion limits it to schizophrenia (“on the latter”).
5. 9.6 — Trailing elaboration kept: The SSRI/SNRI interaction (line 560) keeps “resolved by reducing sarcosine to 1 g or venlafaxine”.

Fixes 11/03/2026 14:19

1. 1.1 — Overgeneralized pooled-trial claim: Changed action_1_sub from “Used in every pooled trial” to “Used in every trial of an independent meta-analysis”, matching the ER’s Marchi 2021 scope.
2. 4.5 — Gloss repeats time value: Replaced time_2_sub “Compared with a standard antidepressant” with “Sarcosine as sole treatment” (ER: sole treatment versus citalopram).
3. 7.1 / 7.4 — Lede use and scope: Rewrote the lede to state sarcosine is “studied for mental illness and aging” and limited the disagreement to schizophrenia with “though reviews disagree on the latter” (70 words).
4. 9.6 — Trailing elaboration kept: Removed “resolved by reducing sarcosine to 1 g or venlafaxine” from the SSRI/SNRI interaction, leaving “irritability or hypomania”.